Join the Lung Cancer group to help and get support from people like you.
Lung Cancer News (Page 5)
Related terms: Cancer, Bronchogenic Carcinoma, Cancer, Lung
Report Highlights Big Gaps in Cancer Outcomes Based on Race
WEDNESDAY, May 15, 2024 – U.S. cancer death rates are continuing to drop, falling by 33% between 1991 and 2020. However, not all Americans are reaping the benefits from advances in cancer...
AACR Delivers Report on Disparities in Cancer Progress
WEDNESDAY, May 15, 2024 – In its biennial Cancer Disparities Progress Report published today, the American Association for Cancer Research presents the latest statistics on disparities in cancer...
Americans of Pacific Island Ethnicity Have Up to Triple the Rate of Cancer Deaths
WEDNESDAY, May 1, 2024 – Native Hawaiian and other Pacific Islander people have cancer death rates that are two to three times higher than they are in whites, new data shows. The first-of-its-kind...
FDA Approves Tabrecta (capmatinib) for Metastatic Non-Small Cell Lung Cancer with METex14
EAST HANOVER, N.J., May 6, 2020 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) approved Tabrecta™ (capmatinib, formerly INC280), an oral MET inhibitor for adul...
FDA Approves Genentech’s Tecentriq in Combination With Chemotherapy for the Initial Treatment of Adults With Extensive-Stage Small Cell Lung Cancer
South San Francisco, CA – March 18, 2019 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq...
FDA Approves Keytruda (pembrolizumab) in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
KENILWORTH, N.J.--(BUSINESS WIRE) October 30, 2018 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has...
FDA Approves Lorbrena (lorlatinib) for Previously-Treated ALK-Positive Metastatic Non-Small Cell Lung Cancer
November 2, 2018 Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved Lorbrena [lor-BREN-ah] (lorlatinib), a third-generation anaplastic lymphoma...
FDA Approves Vizimpro (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
September 27, 2018 - Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved Vizimpro [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line...
FDA Approves Opdivo (nivolumab) for Certain Patients with Previously Treated Small Cell Lung Cancer
PRINCETON, N.J.--(BUSINESS WIRE)--August 17, 2018 – Bristol-Myers Squibb Company (NYSE:BMY) today announced that Opdivo (nivolumab) received approval from the U.S. Food and Drug Administration (FDA)...
FDA Approves Tagrisso (osimertinib) as First-Line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer
18 April 2018 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic non-small cell...
FDA Approves Alecensa (alectinib) as First-Line Treatment for ALK-Positive Metastatic Non-Small Cell Lung Cancer
South San Francisco, CA – November 6, 2017 - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved the...
FDA Approves Mvasi (bevacizumab-awwb), a Biosimilar to Avastin
September 14, 2017 – The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is...
FDA Approves Merck’s Keytruda (pembrolizumab) for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer
KENILWORTH, N.J.--(BUSINESS WIRE) October 24, 2016 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has...
FDA Approves Genentech’s Cancer Immunotherapy Tecentriq (Atezolizumab) for People with a Specific Type of Metastatic Lung Cancer
South San Francisco, CA – October 18, 2016 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq...
FDA Expands Use of Xalkori (crizotinib) to Treat ROS-1 Positive Non-Small Cell Lung Cancer
March 11, 2016 – The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1...